These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 22481387)
21. Playing safe and preserving integrity: making the FDA model work. Wittes J Stat Med; 2004 May; 23(10):1523-5. PubMed ID: 15122731 [TBL] [Abstract][Full Text] [Related]
22. Data Safety Monitoring Boards. Thatte U; Kulkarni-Munshi R Natl Med J India; 2007; 20(4):165-8. PubMed ID: 18085119 [No Abstract] [Full Text] [Related]
23. Analysis of spontaneous adverse drug reaction (ADR) reports using supplementary information. Ghosh P; Dewanji A Stat Med; 2011 Jul; 30(16):2040-55. PubMed ID: 21544847 [TBL] [Abstract][Full Text] [Related]
24. Comparing reporting rates of adverse events between drugs with adjustment for year of marketing and secular trends in total reporting. Tsong Y J Biopharm Stat; 1995 Mar; 5(1):95-114. PubMed ID: 7613562 [TBL] [Abstract][Full Text] [Related]
25. Clinical trials and public trust. Kennedy D Science; 2004 Dec; 306(5702):1649. PubMed ID: 15576574 [No Abstract] [Full Text] [Related]
28. Data safety monitoring boards: a word from a sponsor (NHLBI). Mondoro TH Transfusion; 2009 Aug; 49(8):1537-9. PubMed ID: 19413736 [No Abstract] [Full Text] [Related]
29. A decade of WHO Information Exchange System 'ALERT'. Griffin JP Adverse Drug React Toxicol Rev; 1999 Aug; 18(3):117-9. PubMed ID: 10592833 [No Abstract] [Full Text] [Related]
30. The state of dietary supplement adverse event reporting in the United States. Gardiner P; Sarma DN; Low Dog T; Barrett ML; Chavez ML; Ko R; Mahady GB; Marles RJ; Pellicore LS; Giancaspro GI Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):962-70. PubMed ID: 18613260 [TBL] [Abstract][Full Text] [Related]
31. Issues in regulatory guidelines for data monitoring committees. DeMets D; Califf R; Dixon D; Ellenberg S; Fleming T; Held P; Julian D; Kaplan R; Levine R; Neaton J; Packer M; Pocock S; Rockhold F; Seto B; Siegel J; Snapinn S; Stump D; Temple R; Whitley R Clin Trials; 2004; 1(2):162-9. PubMed ID: 16281888 [TBL] [Abstract][Full Text] [Related]
32. Clinical trials in children--How are they implemented? Hirtz DG; Gilbert PR; Terrill CM; Buckman SY Pediatr Neurol; 2006 Jun; 34(6):436-8. PubMed ID: 16765820 [TBL] [Abstract][Full Text] [Related]
33. Drug safety. Gaps in the safety net. Couzin J Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480 [No Abstract] [Full Text] [Related]
34. Reporting of adverse drug events: a key to postmarketing drug safety. Rheinstein PH Am Fam Physician; 1992 Sep; 46(3):873-4. PubMed ID: 1514478 [No Abstract] [Full Text] [Related]
35. The IRB is not a data and safety monitoring board. Bankert E; Amdur R IRB; 2000; 22(6):9-11. PubMed ID: 11883486 [No Abstract] [Full Text] [Related]
36. The cost of clear skin: balancing the social and safety costs of iPLEDGE with the efficacy of Accutane (isotretinoin). Doshi A Seton Hall Law Rev; 2007; 37(2):625-60. PubMed ID: 17294569 [No Abstract] [Full Text] [Related]
37. Conflicts of interest in data monitoring of industry versus publicly financed clinical trials. Lachin JM Stat Med; 2004 May; 23(10):1519-21. PubMed ID: 15122730 [TBL] [Abstract][Full Text] [Related]
38. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers. Fleuranceau-Morel P Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550 [TBL] [Abstract][Full Text] [Related]
39. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. Seruga B; Sterling L; Wang L; Tannock IF J Clin Oncol; 2011 Jan; 29(2):174-85. PubMed ID: 21135271 [TBL] [Abstract][Full Text] [Related]
40. Drug safety: are we making progress?: comment on "pooled analysis of rofecoxib placebo-controlled clinical trial data". Luepker RV Arch Intern Med; 2010 Jan; 170(2):202. PubMed ID: 20101016 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]